Immunogenicity and Safety of Influenza and COVID-19 Multicomponent Vaccine in Adults Age 50 and Older - For The Media

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, MAY 7, 2025

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.5646?guestAccessKey=143c6ea1-0112-4ea2-8e85-b19e45dd9773&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050725

About The Study: In this phase 3 study, mRNA-1083, an investigational, multicomponent vaccine against seasonal influenza and SARS-CoV-2, met noninferiority criteria and induced higher immune responses than recommended standard care influenza (standard and high dose) and COVID-19 vaccines against all 4 influenza strains (among those ages 50-64), the 3 clinically relevant influenza strains (among those age 65 and older), and SARS-CoV-2 (all ages), with an acceptable tolerability and safety profile.

Corresponding Author: To contact the corresponding author, Amanda K. Rudman Spergel, MD, email Amanda.RudmanSpergel@modernatx.com.

(doi:10.1001/jama.2025.5646)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.